Xiaolei Zhu

Summary

Affiliation: Stony Brook University
Country: USA

Publications

  1. ncbi request reprint Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis
    Xiaolei Zhu
    Division of Nephrology, SUNY at Stony Brook, NY, USA
    Am J Kidney Dis 49:186-93. 2007
  2. doi request reprint Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
    Shenhong Wu
    Division of Medical Oncology, Department of Medicine, State University of New York, Stony Brook, NY 11794 9447, USA
    Lancet Oncol 9:117-23. 2008
  3. pmc Bevacizumab increases risk for severe proteinuria in cancer patients
    Shenhong Wu
    Division of Hematology and Oncology, Stony Brook University Medical Center, Stony Brook, New York, USA
    J Am Soc Nephrol 21:1381-9. 2010
  4. doi request reprint Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis
    Xiaolei Zhu
    Kidney Specialists of Long Island, Port Jefferson Station, NY, USA
    Acta Oncol 48:9-17. 2009

Detail Information

Publications4

  1. ncbi request reprint Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis
    Xiaolei Zhu
    Division of Nephrology, SUNY at Stony Brook, NY, USA
    Am J Kidney Dis 49:186-93. 2007
    ..We performed a systematic review and meta-analysis of published clinical trials of bevacizumab to quantify the risk of proteinuria and hypertension...
  2. doi request reprint Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
    Shenhong Wu
    Division of Medical Oncology, Department of Medicine, State University of New York, Stony Brook, NY 11794 9447, USA
    Lancet Oncol 9:117-23. 2008
    ..The aim of this study is to gain a better understanding of the overall risk of hypertension in patients with cancer who receive sorafenib...
  3. pmc Bevacizumab increases risk for severe proteinuria in cancer patients
    Shenhong Wu
    Division of Hematology and Oncology, Stony Brook University Medical Center, Stony Brook, New York, USA
    J Am Soc Nephrol 21:1381-9. 2010
    ..39). In conclusion, the addition of bevacizumab to chemotherapy significantly increases the risk for high-grade proteinuria and nephrotic syndrome...
  4. doi request reprint Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis
    Xiaolei Zhu
    Kidney Specialists of Long Island, Port Jefferson Station, NY, USA
    Acta Oncol 48:9-17. 2009
    ..We here performed a systematic review and meta-analysis of published clinical trials to determine its overall risk...